FLGT
Fulgent Genetics, Inc. NASDAQ Listed Sep 29, 2016$18.00
+1.69%
vs $17.70
Mkt Cap $554.0M
52w Low $13.79
24.7% of range
52w High $30.85
50d MA $16.68
200d MA $21.71
P/E (TTM)
-9.1x
EV/EBITDA
—
P/B
0.5x
Debt/Equity
0.0x
ROE
-5.4%
P/FCF
-4.5x
RSI (14)
48.80
ATR (14)
$0.79
Beta
0.89
50d MA
$16.68
200d MA
$21.71
Avg Volume
485.5K
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
4978 Santa Anita Avenue · El Monte, CA 91780 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | BMO | -0.35 | -0.36 | -3.4% | 15.19 | -7.6% | -7.0% | +7.0% | -1.5% | +0.1% | +1.3% | — |
| Feb 27, 2026 | BMO | 0.03 | 0.16 | +433.3% | 24.76 | -23.2% | -38.1% | -7.4% | -2.9% | +1.5% | +1.9% | — |
| Nov 7, 2025 | BMO | -0.24 | 0.14 | +158.3% | 22.31 | +7.8% | +18.2% | +3.0% | +4.5% | +2.5% | +1.8% | — |
| Aug 1, 2025 | BMO | -0.23 | 0.07 | +130.4% | 17.18 | +12.0% | +7.9% | -0.9% | +13.2% | -0.5% | -1.3% | — |
| May 2, 2025 | BMO | -0.19 | 0.04 | +121.1% | 17.25 | +5.5% | +19.1% | -4.8% | -3.8% | -0.9% | -0.5% | — |
| Feb 28, 2025 | BMO | -0.31 | 0.04 | +112.9% | 15.69 | +1.7% | -1.5% | -1.1% | +1.6% | +7.3% | +7.5% | — |
| Nov 8, 2024 | BMO | -0.19 | 0.31 | +263.2% | 22.02 | -0.8% | -11.8% | +3.1% | -4.4% | -3.9% | -3.4% | — |
| Aug 2, 2024 | BMO | -0.31 | 0.15 | +148.4% | 23.57 | -5.4% | +6.3% | -5.5% | +2.6% | -3.2% | +4.4% | — |
| May 3, 2024 | BMO | -0.33 | -0.01 | +97.0% | 21.24 | -3.5% | +1.2% | -0.0% | -0.8% | -0.2% | +2.4% | — |
| Feb 28, 2024 | BMO | -0.30 | 0.28 | +193.3% | 25.48 | +0.0% | -8.1% | -3.6% | +3.0% | +2.2% | -2.2% | — |
| Nov 3, 2023 | BMO | -0.33 | -0.39 | -18.2% | 23.79 | +2.4% | +13.2% | +0.7% | -2.3% | -0.2% | -1.3% | — |
| Aug 4, 2023 | BMO | -0.33 | -0.08 | +75.8% | 40.08 | +9.8% | -3.0% | -12.8% | -1.6% | -1.6% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $27.16 | $27.47 | +1.1% | +4.5% | +2.5% | +1.8% | -1.7% | -1.0% |
| Aug 5 | UBS | Upgrade | Neutral → Buy | — | $18.36 | $19.55 | +6.5% | +13.2% | -0.5% | -1.3% | -0.2% | +1.2% |
| Aug 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $18.53 | $18.56 | +0.2% | -0.9% | +13.2% | -0.5% | -1.3% | -0.2% |
| May 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $19.56 | $19.65 | +0.5% | -3.8% | -0.9% | -0.5% | +6.1% | +2.1% |
| May 5 | Raymond James | Maintains | Outperform → Outperform | — | $20.54 | $19.86 | -3.3% | -4.8% | -3.8% | -0.9% | -0.5% | +6.1% |
| Mar 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $15.28 | $15.07 | -1.4% | +1.6% | +7.3% | +7.5% | +3.9% | -9.2% |
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $19.43 | $19.84 | +2.1% | +3.1% | -4.4% | -3.9% | -3.4% | -2.7% |
| Mar 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $23.22 | $23.22 | +0.0% | +0.6% | +1.2% | -3.0% | +1.5% | -2.1% |
| Oct 16 | Piper Sandler | Maintains | Neutral → Neutral | — | $24.90 | $24.89 | -0.0% | +0.9% | -0.3% | +0.5% | +1.0% | -0.2% |
| Mar 2 | Credit Suisse | Maintains | Outperform → Outperform | — | $31.85 | $31.39 | -1.4% | +4.9% | +1.0% | -7.5% | -0.1% | +0.8% |
| Dec 8 | Piper Sandler | Downgrade | Overweight → Neutral | — | $37.07 | $35.67 | -3.8% | -9.1% | +1.1% | -2.1% | +1.0% | +0.0% |
| Nov 18 | Raymond James | Maintains | Outperform → Outperform | — | $35.89 | $37.24 | +3.8% | +3.2% | -0.9% | -2.0% | +1.4% | +1.1% |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $39.24 | $38.73 | -1.3% | -8.5% | +3.1% | -2.9% | -0.2% | +3.2% |
| Nov 14 | Credit Suisse | Maintains | Outperform → Outperform | — | $39.24 | $38.73 | -1.3% | -8.5% | +3.1% | -2.9% | -0.2% | +3.2% |
| Aug 25 | Credit Suisse | Maintains | Outperform → Outperform | — | $46.96 | $47.77 | +1.7% | +2.4% | -3.6% | -3.5% | -1.4% | -1.5% |
| May 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $54.45 | $54.31 | -0.3% | -1.5% | +5.7% | -2.2% | +3.8% | -2.7% |
| Jan 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $60.72 | $60.10 | -1.0% | +4.6% | -2.4% | -2.4% | +3.5% | +2.0% |
| Aug 10 | Credit Suisse | Maintains | Underperform → Underperform | — | $109.76 | $95.00 | -13.4% | -11.3% | -2.2% | +4.2% | -4.9% | +1.9% |
| Mar 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $85.53 | $110.88 | +29.6% | +8.0% | +2.4% | +15.9% | -11.3% | +5.2% |
| Feb 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $110.49 | $112.30 | +1.6% | +24.8% | -18.2% | +12.3% | -5.9% | +18.7% |
| Jan 8 | Credit Suisse | Downgrade | Neutral → Underperform | — | $70.84 | $71.00 | +0.2% | -10.6% | -2.0% | +12.6% | -0.1% | -1.1% |
| Nov 24 | BTIG | Downgrade | Buy → Neutral | — | $43.60 | $42.35 | -2.9% | -15.3% | -1.2% | +11.3% | +10.6% | +2.1% |
| Sep 25 | Credit Suisse | Maintains | Neutral → Neutral | — | $39.52 | $39.53 | +0.0% | -0.4% | -1.1% | +7.4% | -4.2% | +1.4% |
| Aug 20 | Oppenheimer | Maintains | Outperform → Outperform | — | $44.01 | $45.38 | +3.1% | +14.8% | -5.0% | -4.9% | +0.6% | -2.5% |
| Jul 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $19.51 | $19.92 | +2.1% | +35.6% | -2.9% | -0.1% | +1.8% | +0.9% |
| Jun 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.50 | $19.30 | +17.0% | -1.0% | +2.4% | +0.5% | +2.3% | +1.8% |
| May 29 | BTIG | Maintains | Buy → Buy | — | $16.06 | $16.70 | +4.0% | +8.5% | +3.3% | +1.6% | -3.7% | -4.0% |
| May 5 | Credit Suisse | Maintains | Neutral → Neutral | — | $16.48 | $16.91 | +2.6% | -23.5% | +15.5% | +7.6% | +5.7% | +1.1% |
| Nov 5 | Piper Sandler | Upgrade | Neutral → Overweight | — | $9.40 | $11.50 | +22.3% | +38.4% | -8.3% | +3.3% | +28.4% | -6.1% |
| Apr 26 | Credit Suisse | Downgrade | Outperform → Neutral | — | $7.35 | $7.25 | -1.4% | -6.8% | -3.8% | +0.9% | +3.0% | +0.7% |
| May 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $3.88 | $3.80 | -2.0% | -2.3% | -2.4% | +2.7% | -2.4% | +0.0% |
| Mar 1 | Piper Sandler | Downgrade | Overweight → Neutral | — | $4.79 | $4.58 | -4.4% | -10.0% | -11.4% | -1.8% | +1.3% | +0.3% |
| Mar 1 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.79 | $4.58 | -4.4% | -10.0% | -11.4% | -1.8% | +1.3% | +0.3% |
| Nov 7 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.05 | $3.33 | -17.8% | -14.3% | -1.2% | -2.2% | -1.0% | -1.8% |
| Aug 8 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.14 | $5.76 | -6.2% | -12.2% | +4.6% | +2.5% | -0.3% | +2.8% |
| Oct 24 | Credit Suisse | Maintains | Outperform → Outperform | — | $8.88 | $8.85 | -0.3% | +2.6% | +2.1% | -3.0% | -0.3% | +1.1% |
| Oct 24 | BTIG Research | Maintains | Buy → Buy | — | $8.88 | $8.85 | -0.3% | +2.6% | +2.1% | -3.0% | -0.3% | +1.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Gao Hanlin | Chief Scientific Officer | Sell | 1,688 | $17.89 | $30K | 990,374 | +7.50% | +2.32% |
| Jun 2, 2026 | Xie Jian | President and COO | Sell | 2,146 | $17.89 | $38K | 367,605 | +7.50% | +2.32% |
| May 27, 2026 | Gao Hanlin | Chief Scientific Officer | Sell | 945 | $17.60 | $17K | 992,062 | -0.55% | +7.50% |
| May 27, 2026 | Xie Jian | President and COO | Sell | 1,201 | $17.60 | $21K | 369,751 | -0.55% | +7.50% |
8-K · 8.01
!! High
Fulgent Genetics, Inc. -- 8-K 8.01: Material Event / Announcement
Fulgent Genetics announced a material event but the specific details are contained in the attached press release exhibit, requiring investors to review the full disclosure for impact assessment.
Jun 2
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I need more details about the executive change to provide meaningful analysis. Could you clarify:
1. Which company (CNVS or FLGT)?
2. What position changed?
3. Is this a departure, hire, or promotion?
4. Who is involved?
Without these specifics, I cannot write an accurate assessment of stock implications.
Apr 15
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
OraSure's stabilizing public health funding and near-term catalysts position it for revenue growth and margin expansion, making OSUR attractive for investors seeking profitability turnaround potential.
Mar 30
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
FLGT completed a $43M acquisition, which could accelerate growth and market expansion, though investors should monitor integration costs and whether synergies justify the purchase price.
Mar 17
8-K · 7.01
! Medium
Fulgent Genetics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Fulgent Genetics updated its investor presentation on February 27, 2026, providing current business summaries and updates available on its investor relations website.
Feb 27
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 1,289,000 | $20M | Added | Mar 2026 |
| 2 | Acadian Asset Management Llc | 1,233,951 | $20M | Added | Mar 2026 |
| 3 | Morgan Stanley | 630,506 | $17M | Added | Dec 2025 |
| 4 | Vanguard Capital Management Llc | 880,150 | $14M | New | Mar 2026 |
| 5 | Connor, Clark & Lunn Investment Management Ltd. | 374,825 | $10M | Added | Dec 2025 |
| 6 | D.e. Shaw & Co | 486,770 | $8M | Reduced | Mar 2026 |
| 7 | Jpmorgan Chase & Co | 460,363 | $7M | Added | Mar 2026 |
| 8 | Millennium Management | 401,819 | $6M | Reduced | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 322,189 | $5M | Added | Mar 2026 |
| 10 | Jane Street Group, Llc | 149,988 | $4M | Added | Dec 2025 |
| 11 | Ubs Group Ag | 240,759 | $4M | Added | Mar 2026 |
| 12 | Peapod Lane Capital Llc | 220,627 | $3M | Added | Mar 2026 |
| 13 | Vanguard Portfolio Management Llc | 215,854 | $3M | New | Mar 2026 |
| 14 | Northern Trust Corp | 182,113 | $3M | Added | Mar 2026 |
| 15 | Wells Fargo & Company/mn | 147,135 | $2M | New | Mar 2026 |
| 16 | Barclays Plc | 141,011 | $2M | Reduced | Mar 2026 |
| 17 | Quantinno Capital Management Lp | 137,479 | $2M | Added | Mar 2026 |
| 18 | Bank Of America Corp /de/ | 120,583 | $2M | Reduced | Mar 2026 |
| 19 | Nuveen, Llc | 104,049 | $2M | Reduced | Mar 2026 |
| 20 | Russell Investments Group, Ltd. | 93,481 | $1M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$554.0M
Enterprise Value
$217.9M
P/E (TTM)
-9.14x
Forward P/E
—
PEG Ratio
-0.34x
P/B
0.50x
P/S
1.72x
P/FCF
-4.46x
EV/EBITDA
—
Shares Out
30.8M
Financials (TTM)
Revenue
$322.7M
Net Income
-$60.5M
EBITDA
-$45.8M
Free Cash Flow
-$124.2M
Op Cash Flow
-$101.6M
EPS Basic
$-1.97
EPS Diluted
$-1.97
EPS Forward
$-1.36
Gross Margin
40.6%
Op Margin
-28.2%
Net Margin
-18.8%
Balance Sheet
Total Assets
$1.21B
Total Liab.
$106.8M
Total Equity
$1.11B
Cash
$336.1M
LT Debt
$0
Book Value/Sh
$35.96
Debt/Equity
0.00x
Current Ratio
6.48
Quick Ratio
6.48
Returns & Growth
ROE
-5.4%
ROA
-5.0%
ROIC
-7.1%
Rev Growth YoY
+13.8%
EPS Growth YoY
-39.7%
Price Returns
2W
+12.0%
1M
+19.4%
3M
+18.3%
6M
-38.7%
12M
-12.5%
Technicals
52W High
$30.85
52W Low
$13.79
50d MA
$16.68
200d MA
$21.71
RSI (14)
48.80
ATR (14)
$0.79
Beta
0.89
Avg Volume
485K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$36.00
High
$36.00
Low
$36.00
Median
$36.00
Data updated apr 25, 2026 9:20am
· Source: financialmodelingprep.com